Key facts
- Galatea Bio’s last known valuation is $65.3M (Mar 2025).
- It has raised $30.7M across 1 recorded rounds; the latest was PE Growth/Expansion ($5.3M) in Mar 2025.
- Notable investors include Pareto Holdings, F-Prime Capital, Founder Collective, AME Cloud Ventures, Digitalis Ventures — 19 tracked in total.
- Galatea Bio has filed 1 Form D with the SEC, most recently Sep 2024 ($3.7M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Galatea Bio
Funding rounds
1 roundsAbout Galatea Bio
Operator of a biotechnology company intended to improve diagnostic testing and accelerate drug discovery in diverse underserved populations. The company functions as a biosample to a bioinformatics platform for powering genomic discovery in understudied populations and identifies patients at risk of suffering severe multi-inflammatory syndromes or infections, enabling medical professionals to improve diagnostic testing and accelerate drug discovery in diverse underserved populations.
- Sector
- Healthcare
- HQ
- Miami Lakes, FL, United States
- Founded
- 2020
- Employees
- 35
- Website
- galatea.bio/
- Ownership
- Privately Held (backing)
Galatea Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Galatea Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Galatea Bio in its N-PORT filings yet. We sweep new filings monthly.